Benzinga's Top Initiations
- Analysts at JMP Securities initiated coverage on Myovant Sciences Ltd (NYSE: MYOV) with a Market Outperform rating. The price target for Myovant Sciences is set to $23. Myovant Sciences shares closed at $11.25 on Friday.
- Analysts at Brean Capital initiated coverage on Netflix, Inc. (NASDAQ: NFLX) with a Buy rating. The price target for Netflix is set to $145. Netflix shares closed at $115.21 on Friday.
- Analysts at Goldman Sachs initiated coverage of International Flavors & Fragrances Inc (NYSE: IFF) with a Neutral rating. The price target for International Flavors & Fragrances is set to $121.50. International Flavors & Fragrances shares closed at $119.78 on Friday.
- Analysts at SunTrust Robinson Humphrey initiated coverage on Ra Pharmaceuticals Inc (NASDAQ: RARX) with a Buy rating. The price target for Ra Pharmaceuticals is set to $32. Ra Pharmaceuticals shares closed at $13.29 on Friday.
- Morgan Stanley initiated coverage on ZTO Express (Cayman) Inc (ADR) (NYSE: ZTO) with a Overweight rating. The price target for ZTO Express is set to $20. ZTO Express shares closed at $16.30 on Friday.
- Analysts at Cowen & Co initiated coverage on Sito Mobile Ltd (NASDAQ: SITO) with a Outperform rating. The price target for Sito Mobile is set to $6. Sito Mobile shares closed at $3.92 on Friday.
- Analysts at Barclays initiated coverage on Myovant Sciences Ltd (NYSE: MYOV) with a Overweight rating. The price target for Myovant Sciences is set to $18. Myovant Sciences shares closed at $11.25 on Friday.
- Analysts at Stifel Nicolaus initiated coverage on Teekay LNG Partners L.P. (NYSE: TGP) with a Hold rating. The price target for Teekay LNG Partners is set to $14.50. Teekay LNG Partners shares closed at $14.05 on Friday.
- Credit Suisse initiated coverage on > Ra Pharmaceuticals Inc (NASDAQ: RARX) with a Outperform rating. The price target for Ra Pharmaceuticals is set to $19. Ra Pharmaceuticals shares closed at $13.29 on Friday.
- H.C. Wainwright initiated coverage on Kite Pharma Inc (NASDAQ: KITE) with a Buy rating. The price target for Kite Pharma is set to $78. Kite Pharma shares closed at $51.80 on Friday.
Latest Ratings for MYOV
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2021 | SVB Leerink | Downgrades | Outperform | Market Perform |
| Jan 2021 | Goldman Sachs | Downgrades | Buy | Neutral |
| Aug 2020 | SVB Leerink | Maintains | Outperform |
View More Analyst Ratings for MYOV
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Top InitiationsInitiation Analyst Ratings
